SRR599510
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.570
- INFLAMMATORY_RESPONSE+0.548
- IL6_JAK_STAT3_SIGNALING+0.517
- TNFA_SIGNALING_VIA_NFKB+0.477
- ANGIOGENESIS+0.467
- INTERFERON_GAMMA_RESPONSE+0.454
- KRAS_SIGNALING_UP+0.443
- COMPLEMENT+0.422
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.409
- INTERFERON_ALPHA_RESPONSE+0.403
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.606
- DNA_REPAIR-0.502
- MYC_TARGETS_V1-0.485
- MYC_TARGETS_V2-0.462
- ADIPOGENESIS-0.452
- UNFOLDED_PROTEIN_RESPONSE-0.377
- MITOTIC_SPINDLE-0.375
- PROTEIN_SECRETION-0.350
- FATTY_ACID_METABOLISM-0.333
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.333
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR821602 | GTEX | — | 0.992 |
| 2 | SRR607445 | GTEX | — | 0.966 |
| 3 | SRR1335446 | GTEX | — | 0.958 |
| 4 | SRR608598 | GTEX | — | 0.951 |
| 5 | BS_HHPA8NJ2 | Med | Medulloblastoma | 0.948 |
| 6 | SRR602131 | GTEX | — | 0.941 |
| 7 | SRR1467294 | GTEX | — | 0.941 |
| 8 | SRR1389059 | GTEX | — | 0.937 |
| 9 | SRR1358561 | GTEX | — | 0.936 |
| 10 | SRR1408327 | GTEX | — | 0.936 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.548 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.517 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.477 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.467 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.454 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.443 | Inavolisib | — uncovered |
| COMPLEMENT | 0.422 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.409 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.403 | Inavolisib | — uncovered |
| COAGULATION | 0.371 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.335 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.283 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.252 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.217 | Temsirolimus | — uncovered |
| HYPOXIA | 0.193 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.162 | Inavolisib | — uncovered |
| APOPTOSIS | 0.152 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.143 | Inavolisib | — uncovered |